AstraZeneca Pharmaceuticals LP
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Pascal Soriot
CFO: Marc Dunoyer
CMO: Marc Dunoyer
CTO: Andrew Chen
CCO: Katarina Ageborg
CMO: Sean Bohen
CLINICAL TRIAL:
Please click here for clinical trial information.
JOB OPPORTUNITY:
Please click here for AstraZeneca job opportunities.
PRODUCTS:
AstraZeneca Medications
For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.
FOLLOW AstraZeneca:
Tweets by AstraZeneca
What Science Can Do
2001 articles with AstraZeneca Pharmaceuticals LP
-
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
-
AstraZeneca is attempting to find encouraging news in the failure of its MYSTIC clinical trial, but it doesn’t look good.
-
Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.
-
AstraZeneca Continues to Divest Products, Sells Rights to RSV Drug to Sobi for $1.5 Billion
11/14/2018
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion. -
Sobi™ to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth
11/13/2018
Swedish Orphan Biovitrum AB has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US.
-
As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).
-
Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial
11/10/2018
Fewer MACE events observed with Forxiga vs. placebo, but this finding did not reach statistical significance
-
FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial
11/10/2018
Fewer MACE events observed with FARXIGA vs. placebo, but this finding did not reach statistical significance
-
Indianapolis-based Eli Lilly pulled another BACE therapy from its pipeline, the company announced in a third-quarter conference call.
-
AstraZeneca has spent the last seven years getting hammered by loss of patent protections on older drugs. However, this quarter marked a return to sales growth driven by high demand for its new drugs, especially in the oncology segment.
-
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
-
The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018
11/1/2018
New data on cardiovascular effects of long-term BRILINTA use in patients with a history of heart attack
-
Grünenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and Vimovo
10/30/2018
Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management
-
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
-
Voluntis and AstraZeneca Win Prestigious Prix Galien MedStartUp Award for ‘Best Patient Engagement Technologies’ for eCO
10/29/2018
Voluntis and AstraZeneca announced that they have been awarded the 2018 Prix Galien – MedStartUp Award for Best Patient Engagement Technology for eCO.
-
AstraZeneca's Danilo Verge on Company's Cardiovascular, Renal and Metabolic Approach -- Interview
10/26/2018
AstraZeneca is presenting literally dozens of abstracts at this week’s American Society of Nephrology Kidney Week Annual Meeting in San Diego. Not only does it represent ongoing research on already approved drugs, but promising pipeline products. -
With Money and Equity Changing Hands, Innate Pharma and AstraZeneca Move Deeper into an Immuno-on...
10/23/2018
French company Innate Pharma and UK-based AstraZeneca have had a research collaboration deal in place since 2015. The two companies announced a new multi-term deal to build on that collaboration. -
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
-
AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018
10/22/2018
35 scientific data presentations and publications, including new evidence for LOKELMA™ (sodium zirconium cyclosilicate) in hyperkalemia and FARXIGA® (dapagliflozin) on renal endpoints in type-1 diabetes
-
Updated with Exclusive | ESMO 2018: 60% of Ovarian Cancer Patients Receiving Lynparza Were Progre...
10/22/2018
AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer.